NCT04338620
Inclusion Criteria
Inclusion Criteria: * Age :18 Years to 70 Years (Adult, Older Adult) * ECOG physical score status of 0 or 1 points; * expected survival time ≥ 12 weeks; * Pathological diagnosis with StageIIIA-IIIB NSCLC; * According to the eighth edition of the AJCC/UICC TNM staging system, patients was pathological diagnosed with Stage III-N2 clinically resectable NSCLC. * Patients with at least one evaluable or measurable lesions as per RECIST version 1.1 (CT scan length and diameter of tumor lesion≥10mm, CT scan of lymph node lesion was short diameter≥15mm；) * Patients were newly diagnosed with non-small cell lung cancer, without radiotherapy, chemotherapy, surgery or molecule-targeted treatment. * Patients must have enough cardiopulmonary function for the expected pulmonary resections for lung cancer. * The main organ function meets the following criteria:1) ANC ≥ 1.5×10^9/L; PLT ≥ 100×10^9/L; HB ≥ 90 g/L; 2) TBIL ≤ 1.5×ULN;ALT,AST≤ 2.5×ULN;sCr≤1.5×ULN; 3) INR≤1.5×ULN and APTT≤1.5×ULN;endogenous creatinine clearance rate≥50ml/min(Cockcroft-Gault formula); * Pregnancy test (serum or urine) for woman of childbearing age within 7 days before enrolment must be negative... * Patient has to voluntarily join the study and sign the Informed Consent Form.
Exclusion Criteria
Exclusion Criteria: * Patients with brain metastasis * Patients with autoimmune disease, or history of autoimmune disease... * Subjects who need medical intervention with bronchodilators cannot be included. * Subjects with congenital or acquired immunodeficiency such as HIV infection, active hepatitis B. * Has received a live vaccine within 4 weeks. * Other malignancies within 3 years prior to the first use of the study drug. * Patients with hypertension that is difficult to control. * Patients with myocardial ischemia and myocardial infarction above class II. * Severe infection within 4 weeks before the first administration. * Allogeneic organ transplantation or hematopoietic stem cell transplantation. * Pregnant or nursing women. * History of hypersensitivity to study drugs. * Participated in other clinical trials within 4 weeks. * History of drug or alcohol abuse. * Investigator-determined inability to meet the research request.
Experimental Arm
- •
Control Arm
- •